Perrigo Company plc - Form 8-K Summary
Business Context and Reporting Period
Perrigo Company plc, a global pharmaceutical company incorporated in Ireland, filed this Current Report on Form 8-K on February 27, 2023. The filing serves to announce the release of earnings results for the fourth quarter and full year ended December 31, 2022. The detailed financial data is contained in the attached press release (Exhibit 99.1) and is not restated within the body of this 8-K document.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It references the existence of both GAAP and non-GAAP financial measures but defers the actual figures to the attached press release.
Material Changes and Adjustments
The Company utilizes non-GAAP measures to exclude items that obscure underlying operational trends. The filing lists the following adjustments applied to the reported results for the periods ended December 31, 2022, and December 31, 2021:
- Amortization expense related to acquired intangible assets.
- Acquisition and integration-related charges and contingent consideration adjustments.
- Restructuring charges and other termination benefits.
- Unusual litigation costs.
- (Gain) loss on divestitures and investment securities.
- Non-GAAP tax adjustments.
- Foreign currency translation movements.
- Impairment charges (specifically noted for 2021 and full-year 2022).
- Loss on early debt extinguishment (full-year 2022).
- Separation and reorganization expense (2021).
- Indirect RX business support costs (2021).
Guidance, Outlook, and Management Commentary
Management states that non-GAAP measures are used for planning, forecasting, and evaluating segment performance. The Company discloses constant currency and organic net sales growth to facilitate peer comparison by excluding the impact of acquisitions, divestitures, and foreign exchange. The filing does not contain specific forward-looking guidance, risk factors, or contingency details beyond the standard disclosure of the adjustments listed above.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific GAAP and non-GAAP revenue, net income, and earnings per share figures.
- Verify the magnitude of the "unusual litigation" and "impairment charges" excluded from non-GAAP results.
- Confirm the impact of foreign currency translation on reported net sales growth.
- Check the details of the "loss on early debt extinguishment" included in the full-year 2022 adjustments.
- Compare the adjusted operating margin trends against peer group performance as suggested by management.